Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T

Li, SQ; Zhang, JS; Chen, L; Xu, HL; He, LP; Liu, L; Zhang, QZ; Yuan, ZT; Shen, JJ; Chen, ZC; Zhang, YZ; Wang, ML; Li, YY; Wang, LL; Fang, LH; Chen, YN; Zhu, W; Li, Y; Luo, L; Wang, YC; Zhang, DS; Dong, YC; Yin, P; Zhang, LH; Li, XP; Hu, XZ; Zheng, ZZ; Yang, Z; Qian, C; Wang, SB

Wang, SB (通讯作者)，920th Hosp Joint Logist Support Force Peoples Libe, Dept Hematol, Kunming 650100, Yunnan, Peoples R China.;Yang, Z; Qian, C (通讯作者)，Chongqing Precis Biotech Co Ltd, Chongqing 400039, Peoples R China.

MOLECULAR THERAPY-ONCOLYTICS, 2023; 29 (): 107

Abstract

CD19-targeted chimeric antigen receptor T lymphocytes (CAR-T) has demonstrated a high proportion of complete remission in the treatment of relapsed re......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索